Joint Advisory Committee Endorses Takeda’s Gout Drug

Drug Industry Daily
A A
A joint FDA advisory committee voted 19 to two on Friday in favor of the benefit-risk profile of Takeda’s Uloric (febuxostat) for treatment of excessive uric acid in the blood of gout patients.

To View This Article:

Login

Subscribe To Drug Industry Daily